Glioma
Conditions
Brief summary
Validation of a new platform for the molecular characterization of patients affected by glioma. The new platform includes a series of faster, less expensive real-time PCR methodologies that, in comparison to standard analyses (DS, MS-PCR), are also characterized by higher sensitivity and consequently can be able to identify mutations in ctDNA extracted from liquid biopsies as well. The development of these assays will allow the analysis of molecular markers alteration even in liquid biopsies, providing a less invasive sampling than tissue biopsies, a procedure that sometimes is characterized by side effects or that allow the collection of few tissues for the histological and molecular diagnosis. This study will not interfere with the patients routine treatment pathway and there will be no deviation from the standard of care: the molecular characterization of the tissues will be performed according to the standard diagnostic routine using the currently approved methodologies. For the retrospective study, it will be used the left-over DNA. For the cohort, that includes the collection and the subsequent analysis of liquid biopsies (prospective study), blood and CSF will be sampled during surgery. The mutations in the molecular markers will be analyzed in tissue as well as in plasma and CFS samples by the new real-time based assays. Then, the qualitative and quantitative values obtained on liquid biopsies with the new methodology will be compared to the results of the standard methodologies already obtained, for diagnostic routine, on surgical tissue samples of the same patients.
Interventions
GENETICvalidation of new technologies
Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
Sponsors
Istituto Cantonale di Patologia
Neurocenter of Southern Switzerland
Ente Ospedaliero Cantonale, Bellinzona
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Retrospective Cohort Inclusion Criteria: * Patient with available tissue material or with available molecular data concerning the tissue biopsy obtained during surgery and analyzed for diagnosis
Exclusion criteria
* Insufficient amount of tumor cells in the tissue biopsy for the molecular characterization * Inability to consent and follow the procedures of the study (for alive patients) Prospective Cohort Inclusion Criteria: * Age ≥ 18 years old * Affected by suspected glioma and requiring surgery * Patient with available tissue material or with available molecular data concerning the tissue biopsy obtained during surgery and analyzed for diagnosis * Written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demonstration that the new methodology improves the features | 2 hours | Demostrate that are found at least the same number of mutations in comparison with respect to standard tests |
Countries
Switzerland
Contacts
Primary ContactMilo Frattini, PhD
Outcome results
None listed